New surgical approach under investigation for chronic cystoid DME

Article

Vitrectomy with drainage of cystoid spaces is being evaluated as a new surgical treatment for patients with chronic cystoid diabetic macular edema (DME) who are unresponsive to other interventions and who have minimal or no leakage on fluorescein angiography and good foveal capillary perfusion, said Hilel Lewis, MD, director, Cole Eye Institute, Cleveland Clinic, Cleveland, OH.

Vitrectomy with drainage of cystoid spaces is being evaluated as a new surgical treatment for patients with chronic cystoid diabetic macular edema (DME) who are unresponsive to other interventions and who have minimal or no leakage on fluorescein angiography and good foveal capillary perfusion, said Hilel Lewis, MD, director, Cole Eye Institute, Cleveland Clinic, Cleveland, OH.

Dr. Lewis described the surgery, preliminary results and the possible mechanism for its promise. The procedure involves making a superficial incision into the cysts and using instrumentation to remove the accumulated intraretinal fluid. Initial results from 12 patients with prominent cystoid changes on OCT suggested that the procedure might decrease or resolve the DME and stabilize or improve the vision. None of the patients in that series experienced any worsening of their DME and mean visual acuity for the group improved from 20/220 to 20/123. Two-thirds of the patients experienced a 2-line or greater gain.

The potential benefit may be explained by the understanding that in eyes with chronic DME, there can be damage to the retinal pigment epithelium that interferes with its ability to reabsorb the fluid into the choriocapillaris.

"Even if the retinal vasculature is re-established by photocoagulation or by treatment with pharmacotherapy, the macular edema persists and is not able to reabsorb the fluid," Dr. Lewis said. "In this setting, surgical fluid removal could potentially be beneficial."

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.